StreetInsider.com News Articles

Form SCHEDULE 13G Evommune, Inc. Filed by: Point72 Asset Management, L.P.

Thu, 16 Jul 2026 17:03:00 -0400

si-local-file:///var/storage/secattach/20260716/26780475.html

Form SCHEDULE 13G Evommune, Inc. Filed by: Point72 Asset Management, L.P.

Thu, 16 Jul 2026 17:03:00 -0400

si-local-file:///var/storage/secattach/20260716/26780475.html

Form 4 Evommune, Inc. For: Jul 08 Filed by: Carver Kyle

Fri, 10 Jul 2026 20:00:00 -0400

si-local-file:///var/storage/secattach/20260710/26758281.html

Form 4 Evommune, Inc. For: Jul 08 Filed by: Carver Kyle

Fri, 10 Jul 2026 20:00:00 -0400

si-local-file:///var/storage/secattach/20260710/26758281.html

Form 4 Evommune, Inc. For: Jul 07 Filed by: KIRSCH ARTHUR S

Wed, 08 Jul 2026 20:00:00 -0400

si-local-file:///var/storage/secattach/20260708/26748714.html

Form 4 Evommune, Inc. For: Jul 07 Filed by: KIRSCH ARTHUR S

Wed, 08 Jul 2026 20:00:00 -0400

si-local-file:///var/storage/secattach/20260708/26748714.html

Evommune Inc (EVMN) PT Lowered to $26 at Morgan Stanley

Tue, 30 Jun 2026 08:10:19 -0400

Morgan Stanley analyst Judah Frommer lowered the price target on Evommune Inc (NYSE: EVMN) to $26.00 (from $55.00) while maintaining a Overweight rating.

H.C. Wainwright Downgrades Evommune Inc (EVMN) to Neutral

Tue, 30 Jun 2026 06:47:24 -0400

H.C. Wainwright analyst Mitchell Kapoor downgraded Evommune Inc (NYSE: EVMN) from Buy to Neutral.

The analyst comments "CSU primary endpoint failure removes a core value driver; removing CSU from our model and downgrading to Neutral. EVO756 failed to meet the Phase 2b primary endpoint of mean change in UAS7 at Week 12 in moderate-to-severe antihistamine-refractory CSU across all tested doses, and management no longer plans to pursue CSU development. This is materially damaging to EVMN because CSU was the lead EVO756 indication and the primary value driver for MRGPRX2 before the EVO301 IL-18 AD win created a temporary dual-threat setup in

H.C. Wainwright Downgrades Evommune Inc (EVMN) to Neutral

Tue, 30 Jun 2026 06:47:24 -0400

H.C. Wainwright analyst Mitchell Kapoor downgraded Evommune Inc (NYSE: EVMN) from Buy to Neutral.

Evommune Inc (EVMN) PT Lowered to $28 at Clear Street

Mon, 29 Jun 2026 16:11:52 -0400

Clear Street analyst Kaveri Pohlman lowered the price target on Evommune Inc (NYSE: EVMN) to $28.00 (from $53.00) while maintaining a Buy rating.

Raymond James Downgrades Evommune Inc (EVMN) to Outperform

Mon, 29 Jun 2026 09:53:33 -0400

Raymond James analyst Martin Auster downgraded Evommune Inc (NYSE: EVMN) from Strong Buy to Outperform with a price target of $32.00 (from $52.00).

The analyst comments "This morning, Evommune (EVMN) announced that the Ph2b CSU trial for EVO756 did not meet its primary endpoint. While precedent failure in CSU with this MoA had subdued investor expectations, the total lack of effect of this MoA in CSU remains disappointing. Additional opportunities for EVO756 in AD and migraine remain open, and there is limited read-through from CSU failure, in our view. EVMN has two Ph2 stage clinical programs, and we expect investors to

Raymond James Downgrades Evommune Inc (EVMN) to Outperform

Mon, 29 Jun 2026 09:53:33 -0400

Raymond James analyst Martin Auster downgraded Evommune Inc (NYSE: EVMN) from Strong Buy to Outperform with a price target of $32.00 (from $52.00).

William Blair Downgrades Evommune Inc (EVMN) to Market Perform

Mon, 29 Jun 2026 09:30:09 -0400

William Blair analyst Matt Phipps downgraded Evommune Inc (NYSE: EVMN) from Outperform to Market Perform.

The analyst comments "Stock Thoughts: We believe shares will trade down to the midteens following the removal of EVO756 in CSU from the valuation. While a separate Phase II trial with EVO756 in atopic dermatitis (AD) is reading out in the third quarter, we expect investor expectations for that trial to be very low. A separate Phase IIb trial in migraine is expected to start enrolling patients in the near term, where we believe there is rationale for MRGPRX2 inhibition based on clinical results with PACAP

William Blair Downgrades Evommune Inc (EVMN) to Market Perform

Mon, 29 Jun 2026 09:30:09 -0400

William Blair analyst Matt Phipps downgraded Evommune Inc (NYSE: EVMN) from Outperform to Market Perform.

Form 424B3 Evommune, Inc.

Mon, 29 Jun 2026 08:35:00 -0400

si-local-file:///var/storage/secattach/20260629/26702709.html

Form 424B3 Evommune, Inc.

Mon, 29 Jun 2026 08:35:00 -0400

si-local-file:///var/storage/secattach/20260629/26702709.html

Form 8-K Evommune, Inc. For: Jun 29

Mon, 29 Jun 2026 08:32:00 -0400

si-local-file:///var/storage/secattach/20260629/26702675.html

Form 8-K Evommune, Inc. For: Jun 29

Mon, 29 Jun 2026 08:32:00 -0400

si-local-file:///var/storage/secattach/20260629/26702675.html

Evommune's EVO756 fails Phase 2b trial for chronic urticaria

Mon, 29 Jun 2026 08:31:33 -0400

Evommune, Inc. (NYSE: EVMN) announced that its Phase 2b clinical trial of EVO756 in adults with moderate-to-severe chronic spontaneous urticaria (CSU) did not meet its primary endpoint, according to a press release from the clinical-stage biotechnology company.

The randomized, double-blind, placebo-controlled trial enrolled 160 patients in the United States, Europe, Canada, and Japan. Participants received one of three active dose regimens or a placebo. The trial failed to demonstrate a statistically significant mean change in the Urticaria Activity Score over seven days (UAS7) at 12 weeks at any dose tested.

"The lack of efficacy demonstrated at Week 12 in this Phase 2b

Evommune's EVO756 fails Phase 2b trial for chronic urticaria

Mon, 29 Jun 2026 08:31:33 -0400

"The lack of efficacy demonstrated at Week 12 in this Phase 2b

Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria

Mon, 29 Jun 2026 08:30:00 -0400

- Trial did not meet the primary endpoint of mean change in Urticaria Activity Score over seven days (UAS7) at 12 weeks

- Evommune to continue development of EVO756 in Atopic Dermatitis and Migraine

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--

Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced top-line results from its randomized, double-blind, placebo controlled, dose-ranging Phase 2b trial evaluating the efficacy and safety of oral MRGPRX2 antagonist, EVO756, in adults with moderate-to-severe chronic spontaneous urticaria (CSU).

The

Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria

Mon, 29 Jun 2026 08:30:00 -0400

- Trial did not meet the primary endpoint of mean change in Urticaria Activity Score over seven days (UAS7) at 12 weeks

- Evommune to continue development of EVO756 in Atopic Dermatitis and Migraine

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--

The

Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria

Mon, 29 Jun 2026 08:30:00 -0400

- Trial did not meet the primary endpoint of mean change in Urticaria Activity Score over seven days (UAS7) at 12 weeks

- Evommune to continue development of EVO756 in Atopic Dermatitis and Migraine

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--

The

Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria

Mon, 29 Jun 2026 08:30:00 -0400

- Trial did not meet the primary endpoint of mean change in Urticaria Activity Score over seven days (UAS7) at 12 weeks

- Evommune to continue development of EVO756 in Atopic Dermatitis and Migraine

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--

The

Form 4 Evommune, Inc. For: Jun 22 Filed by: Drew Janice Suzann

Wed, 24 Jun 2026 20:01:00 -0400

si-local-file:///var/storage/secattach/20260624/26686879.html